YOLFTbeta
Immunic Inc

Immunic Inc

IMUX · NASDAQ · Healthcare / Biotechnology

7.52USD-0.27 (-3.47%)

Price History

Full chart

Market Stats

Previous Close7.79
Open7.87
Day Range7.52 – 7.87
52-Week Range5.06 – 17.43
Volume105.14K
Market Cap129.76M
P/E (TTM)0.00
Forward P/E0.00
EPS-3.62
Dividend Yield0.00%
Beta1.41
50-Day Avg13.68
200-Day Avg11.31

About

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Erik Lundgren
  • Employees100
  • Headquarters1200 Avenue of the Americas, New York, NY, United States, 10036, USA
  • Websitehttps://imux.com

Leadership

  • Mr. Jason Tardio M.B.A.COO & President · b. 1977
  • Mr. Glenn Whaley CPAChief Financial Officer · b. 1968
  • Mr. Erik LundgrenCEO & Director · b. 1978
  • Dr. Hella KohlhofCo-Founder & Chief Scientific Officer · b. 1973
  • Ms. Jessica BreuVice President of Investor Relations & Communications
  • Mr. Inderpal SinghGeneral Counsel · b. 1966
  • Mr. Patrick WalshChief Business Officer · b. 1983
  • Mr. Werner GladdinesChief Development Officer · b. 1979
  • Dr. Michael A. Panzara M.D., M.P.H.Chief Medical Officer · b. 1967
  • Mr. Chitrang DavéChief Data & Digital Officer

Financials

Income Statement

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue-----6.00K000000000
Growth (%)-------100.00%--------
Cost of Revenue----1.33M206998.00K15.00K50.00K39.00K85.00K77.00K111.00K134.00K168.00K
Gross Profit-----1.33M5.79K-998.00K-15.00K-50.00K-39.00K-85.00K-77.00K-111.00K-134.00K-168.00K
Gross Margin-----96.57%---------
Operating Expense----50.79M41.27M51.66M42.01M36.98M48.93M91.58M119.41M99.11M97.92M103.06M
Operating Income-8.58M-9.58M-31.40M-50.34M-52.12M-41.27M-52.66M-42.02M-37.03M-48.97M-91.67M-119.49M-99.22M-98.05M-103.23M
Operating Margin------687766.67%---------
EBITDA-7.62M-5.64M-31.92M-49.26M-50.79M-39.46M-51.08M-15.14M-36.98M-48.93M-91.58M-86.44M-93.50M-100.37M-97.00M
EBITDA Margin------657633.33%---------
Net Income-5.88M-6.70M-32.72M-47.67M-52.02M-40.97M-52.08M-41.48M-34.83M-44.02M-92.79M-120.41M-93.61M-100.51M-97.17M
Net Income Margin------682816.67%---------
R&D5.51M5.10M21.79M39.48M39.77M30.05M39.34M24.82M22.51M38.64M61.12M71.25M83.22M80.05M81.98M
R&D as % of Total Revenue-----500766.67%---------
Interest Expense9.25M413.00K000000107.00K58.00K85.00K1.04M---
Interest Expense % of Total Revenue-----0.00%---------

Balance Sheet

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.98M20.33M46.59M108.08M89.08M64.03M60.38M14.98M65.95M167.86M139.10M127.75M54.30M40.87M24.05M
Total Liabilities56.84M27.96M5.17M10.52M6.76M5.58M10.34M2.55M7.59M9.08M11.98M14.07M25.37M22.44M30.73M
Total Equity-54.85M-7.63M41.42M97.56M82.33M58.45M50.04M12.43M58.36M158.78M127.11M113.68M28.93M18.43M-6.67M
Cash803.00K4.48M38.19M102.24M83.42M59.99M56.90M13.32M29.37M127.45M86.86M106.75M46.67M35.67M15.48M
Total Debt534.00K------37.19M520.00K976.00K992.00K1.56M1.33M1.00M684.00K
Net Debt-269.00K-4.48M-38.19M-102.24M-83.42M-59.99M-56.90M23.87M-28.85M-126.48M-85.87M-105.18M-45.34M-34.66M-14.80M

Cash Flow

Currency: USD2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-7.83M-9.24M-28.65M-40.83M-49.95M-35.77M-40.40M-43.16M-28.55M-46.12M-83.23M-65.14M-70.83M-84.77M-85.81M
Investing Cash Flow-18.00K-14.59M11.91M-2.04M-1.28M-21.00K-678.00K-415.00K10.54M-146.00K-67.00K-9.74M9.46M-264.00K-161.00K
Financing Cash Flow8.25M27.50M50.45M106.92M32.42M12.37M37.98M4.00K34.90M144.43M42.84M95.76M1.03M74.54M65.58M
Capital Expenditure18.00K261.00K1.48M1.41M2.34M556.00K685.00K597.00K55.00K146.00K67.00K112.00K334.00K264.00K161.00K
Free Cash Flow-7.85M-9.51M-30.13M-42.23M-52.29M-36.33M-41.08M-43.76M-28.60M-46.27M-83.30M-65.26M-71.16M-85.03M-85.97M
Dividends Paid---4.74M-00--------
FCF to OCF100.23%102.82%105.18%103.45%104.68%101.55%101.70%101.38%100.19%100.32%100.08%100.17%100.47%100.31%100.19%
Dividend Paid to FCF----11.23%-0.00%0.00%--------

Earnings

Report DateMay 29, 2014Aug 6, 2014Nov 13, 2014Mar 19, 2015May 12, 2015Jul 30, 2015Nov 5, 2015Mar 8, 2016May 9, 2016Aug 2, 2016Nov 3, 2016Mar 7, 2017May 9, 2017Aug 3, 2017Oct 25, 2017Mar 13, 2018May 8, 2018Aug 7, 2018Nov 7, 2018Mar 4, 2019Jun 21, 2019Aug 8, 2019Nov 7, 2019Mar 16, 2020May 8, 2020Aug 2, 2020Nov 5, 2020Feb 26, 2021May 6, 2021Aug 6, 2021Nov 4, 2021Feb 24, 2022May 10, 2022Aug 4, 2022Nov 3, 2022Feb 23, 2023May 11, 2023Aug 3, 2023Nov 14, 2023Feb 22, 2024May 8, 2024Aug 8, 2024Nov 7, 2024Mar 31, 2025May 15, 2025Aug 7, 2025Nov 13, 2025Feb 26, 2026May 13, 2026Aug 11, 2026Nov 12, 2026
EPS Estimate-20.78-22.02-25.07-23.40-24.76-24.93-23.38-16.79-11.15-13.07-12.96-14.20-14.60-14.13-12.80-12.40-13.60-13.20-11.20-0.14-0.59-6.80-6.50-7.60-0.95-7.27-6.47-0.60-6.85-6.67-7.52-0.76-7.57-7.30-6.95-7.42-4.80-5.12-5.07-0.51-2.65-2.33-2.18-2.38-0.25-0.18-1.77-0.10-0.96-1.24-0.82
EPS Actual-979.60-36.40-23.60-23.60-24.80-25.20-20.40-13.60-12.40-12.00-12.80-14.80-15.60-11.60-12.00-14.00-13.60-12.00-11.20-2.40-0.91-15.20-8.20-7.50-0.79-9.00-7.00-0.46-8.14-8.20-7.60-0.72-7.40-7.20-6.90-5.88-5.80-5.40-5.10-0.48-3.00-2.10-2.40-2.50-0.25-0.20-1.30-0.12-1.08-0.80-
Surprise-4614.15%-65.30%5.86%-0.85%-0.16%-1.08%12.75%19.00%-11.21%8.19%1.23%-4.23%-6.85%17.91%6.25%-12.90%0.00%9.09%0.00%-1614.29%-53.39%-123.53%-26.15%1.32%16.84%-23.80%-8.19%23.33%-18.83%-22.94%-1.06%5.26%2.25%1.37%0.72%20.75%-20.83%-5.47%-0.59%5.88%-13.21%9.87%-10.09%-5.04%0.00%-11.11%26.55%-20.00%-12.50%35.48%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap129.76M
Enterprise Value-26.68M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book1.00
EPS-3.62
Book Value9.35
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-117.73M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-138.17%
Return on Assets-66.80%
Shares Outstanding13.64M
Shares Float11.92M
Beta1.41
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 43.09
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
71.14%
Insiders
0.97%
Retail / Other
27.89%

Top Institutional Holders

  • Aberdeen Group PLC
    824.39K6.04%
  • Bvf Inc
    7.65M5.61%
  • Millennium Management LLC
    740.35K5.43%
  • Avidity Partners Management LP
    669.94K4.91%
  • Jones Hill Capital LP
    539.81K3.96%
  • Vanguard Capital Management, LLC
    5.14M3.77%
  • LAURION CAPITAL MANAGEMENT LP
    3.88M2.85%
  • Morgan Stanley - Brokerage Accounts
    3.29M2.41%
  • Nantahala Capital Management, LLC
    2.51M1.84%
  • 683 Capital Management LLC
    2.45M1.80%
  • Geode Capital Management, LLC
    1.53M1.12%
  • Susquehanna International Group, LLP
    1.03M0.75%
  • Woodline Partners LP
    967.15K0.71%
  • BlackRock Inc
    964.23K0.71%
  • Marshall Wace Asset Management Ltd
    952.97K0.70%
  • Renaissance Technologies Corp
    919.16K0.67%
  • Vanguard Fiduciary Trust Co
    740.54K0.54%

Top Fund Holders

  • abrdn Healthcare Investors
    473.88K3.47%
  • Vanguard MStar Total Stk Mkt Idx Invest
    399.09K2.92%
  • abrdn Life Sciences Investors
    302.89K2.22%

Stock Splits

  • Apr 27, 20261:10
  • Apr 15, 20191:40